Overview

The resistance vignette deploys a single drug and watches resistance to it spread. In practice a programme has choices: which drug to use first, whether to use several at once, and when to change. magenta can represent three strategies, all configured through drug_list_create():

  • multiple first line therapies (MFT), several drugs in use simultaneously, each patient receiving one at random
  • sequential cycling, switching to the next drug once treatment failure passes a threshold
  • temporal cycling, switching on a fixed schedule regardless of failure

This vignette also covers non-malarial fevers, which change how much drug pressure a population experiences without changing the treatment policy at all.


Deploying more than one drug

drugs takes a list, and number_of_drugs has to match its length. Drugs are referred to by zero indexed position, so drug_choice = 0 is the first drug in the list.

drugs <- list(
  magenta:::drug_create_al(),
  magenta:::drug_create_asaq(),
  magenta:::drug_create_dhappq()
)
drug_names <- c("AL", "ASAQ", "DHA-PPQ")

Throughout this vignette we reuse a helper so that the only thing changing between runs is the strategy:

loci <- c("crt 76T", "mdr1 86Y", "mdr1 184F", "mdr1 copy number",
          "kelch13 580Y", "plasmepsin 2-3 copy number")

strategy_list <- function(...) {
  drug_list_create(
    resistance_flag = TRUE,
    number_of_resistance_loci = 6,
    artemisinin_loci = 4,
    cost_of_resistance = rep(1, 6),
    drugs = drugs,
    number_of_drugs = 3,
    ...
  )
}

run_strategy <- function(drug_list, years = 20, seed = 1L) {
  pipeline(EIR = 10, N = 3000, years = years, ft = 0.4,
           num_loci = 6, plaf = rep(0.1, 6),
           update_length = 30, update_save = TRUE,
           human_update_save = TRUE, summary_saves_only = TRUE,
           genetics_df_without_summarising = TRUE,
           drug_list = drug_list, seed = seed)
}

# saved intervals, dropping the final element which is the simulation itself
saved <- function(out) out[seq_len(length(out) - 1)]

af_over_time <- function(out) {
  af <- do.call(rbind, lapply(saved(out), "[[", "af"))
  colnames(af) <- loci
  af
}

tf_over_time <- function(out) {
  unlist(lapply(saved(out), "[[", "overall_treatment_failure"))
}

# treatments given with each drug, per saved interval
usage_over_time <- function(out) {
  use <- do.call(rbind, lapply(saved(out), function(x) {
    x$succesfull_treatments + x$unsuccesful_treatments_lpf
  }))
  colnames(use) <- drug_names
  use
}

Multiple first line therapies

With mft_flag = TRUE, each treated individual is given a drug drawn at random according to partner_drug_ratios. Those ratios are the proportion of treatments that use each drug, and must be the same length as drugs.

out_mft <- run_strategy(
  strategy_list(mft_flag = TRUE, partner_drug_ratios = c(1/3, 1/3, 1/3))
)
## Seed set to 1
## magenta v1.3.8
## Starting Stochastic Simulation for 20 years

head(round(usage_over_time(out_mft), 1), 4)
##      AL ASAQ DHA-PPQ
## [1,] 12    1       2
## [2,] 11    9      10
## [3,] 20    9      13
## [4,] 15   17      13

All three drugs are in use at once, in roughly the requested proportions. An unequal split is simply a different set of ratios, for example partner_drug_ratios = c(0.5, 0.3, 0.2).

Because each drug selects on a different set of loci, MFT spreads the selective pressure out:

plot_af <- function(af, main = "", legend_pos = "topleft") {
  years <- seq_len(nrow(af)) / 12
  matplot(years, af, type = "l", lty = 1, lwd = 2, ylim = c(0, 1),
          col = seq_len(ncol(af)), xlab = "Years", ylab = "Allele frequency",
          main = main)
  legend(legend_pos, legend = colnames(af), col = seq_len(ncol(af)),
         lty = 1, lwd = 2, bty = "n", cex = 0.8)
}

plot_af(af_over_time(out_mft), main = "MFT, equal thirds")

Note that an individual’s drug is cached for 15 days, so someone retreated shortly after a failure receives the same drug rather than a fresh draw.


Sequential cycling

With sequential_cycling set to a proportion, the model watches overall_treatment_failure and moves to the next drug in the list once that threshold is exceeded. sequential_update is the minimum number of years between switches, which stops a noisy failure estimate causing repeated changes.

out_seq <- run_strategy(
  strategy_list(mft_flag = FALSE,
                partner_drug_ratios = c(1, 0, 0),
                drug_choice = 0,
                sequential_cycling = 0.10,
                sequential_update = 3)
)
## Seed set to 1
## magenta v1.3.8
## Starting Stochastic Simulation for 20 years
## Sequential cycling: switched to drug 1
## Sequential cycling: switched to drug 2
## Sequential cycling: switched to drug 0
## Sequential cycling: switched to drug 1
## Sequential cycling: switched to drug 2

The messages record each switch. Plotting which drug is actually being used makes the policy visible:

plot_usage <- function(out, main = "") {
  use <- usage_over_time(out)
  years <- seq_len(nrow(use)) / 12
  matplot(years, use, type = "l", lty = 1, lwd = 2, col = seq_len(ncol(use)),
          xlab = "Years", ylab = "Treatments given", main = main)
  legend("topright", legend = colnames(use), col = seq_len(ncol(use)),
         lty = 1, lwd = 2, bty = "n")
}

plot_usage(out_seq, main = "Sequential cycling at 10% treatment failure")

Three things about sequential cycling are easy to trip over.

  1. The switch is evaluated in R between update intervals, inside pipeline(). It therefore only happens when update_save = TRUE.
  2. It only happens when resistance_flag is TRUE for that year. If you stage resistance so that it is inactive during a burn-in, cycling is inactive then too.
  3. It is skipped entirely when mft_flag = TRUE. MFT and cycling are alternatives, not features that combine.

The drug index wraps around, so after the last drug the policy returns to the first.


Temporal cycling

temporal_cycling switches drug every fixed number of years, whatever the failure rate is doing. It cannot be combined with sequential_cycling; drug_list_create() will stop if both are positive.

out_temporal <- run_strategy(
  strategy_list(mft_flag = FALSE,
                partner_drug_ratios = c(1, 0, 0),
                drug_choice = 0,
                temporal_cycling = 5)
)
## Seed set to 1
## magenta v1.3.8
## Starting Stochastic Simulation for 20 years

plot_usage(out_temporal, main = "Temporal cycling every 5 years")


Comparing strategies

Putting the three side by side on the same seed is the usual starting point for a policy comparison. Here we hold everything else fixed and compare overall treatment failure:

out_single <- run_strategy(
  strategy_list(mft_flag = FALSE, partner_drug_ratios = c(0, 0, 1),
                drug_choice = 2)
)
## Seed set to 1
## magenta v1.3.8
## Starting Stochastic Simulation for 20 years

tfs <- cbind(
  "DHA-PPQ only" = tf_over_time(out_single),
  "MFT"          = tf_over_time(out_mft),
  "Sequential"   = tf_over_time(out_seq),
  "Temporal"     = tf_over_time(out_temporal)
)

years <- seq_len(nrow(tfs)) / 12
matplot(years, tfs, type = "l", lty = 1, lwd = 2, col = seq_len(ncol(tfs)),
        xlab = "Years", ylab = "Overall treatment failure")
legend("topleft", legend = colnames(tfs), col = seq_len(ncol(tfs)),
       lty = 1, lwd = 2, bty = "n")

A single run of a stochastic model is not a result. For anything you intend to report, run many seeds per strategy and summarise the distribution; the differences between strategies here are comparable in size to the variation between seeds.


Non-malarial fevers

Treatment coverage ft applies to clinical malaria. But in a real health system, people are also treated for fevers that are not malaria, either because no test was done or because a test was wrong. Those treatments still expose parasites to the drug, and still put uninfected people into a prophylactic state.

nmf_list_create() controls this. Like the drug constructors, it is currently an internal function and so is called with magenta:::, even though pipeline() documents it as the way to configure non-malarial fevers:

nmf <- magenta:::nmf_list_create(nmf_flag = TRUE, prob_of_testing_nmf = 0.5)
str(nmf[c("nmf_flag", "prob_of_testing_nmf")])
## List of 2
##  $ nmf_flag           : logi TRUE
##  $ prob_of_testing_nmf: num 0.5
  • mean_nmf_frequency is the mean number of days between non-malarial fevers, one value per age bracket, and nmf_age_brackets gives those brackets in days. The defaults are age specific and based on observed fever frequencies.
  • prob_of_testing_nmf is the probability that a non-malarial fever is tested before antimalarials are given. Lowering it increases presumptive treatment.

Adding non-malarial fevers increases the amount of drug in circulation without changing ft:

out_nmf <- pipeline(
  EIR = 10, N = 3000, years = 20, ft = 0.4,
  num_loci = 6, plaf = rep(0.1, 6),
  update_length = 30, update_save = TRUE,
  human_update_save = TRUE, summary_saves_only = TRUE,
  genetics_df_without_summarising = TRUE,
  drug_list = strategy_list(mft_flag = FALSE,
                            partner_drug_ratios = c(0, 0, 1),
                            drug_choice = 2),
  nmf_list = nmf,
  seed = 1L
)
## Seed set to 1
## magenta v1.3.8
## Starting Stochastic Simulation for 20 years

ppq <- "plasmepsin 2-3 copy number"
years <- seq_len(nrow(af_over_time(out_single))) / 12
plot(years, af_over_time(out_single)[, ppq], type = "l", lwd = 2,
     col = "steelblue", ylim = c(0, 1),
     xlab = "Years", ylab = "Plasmepsin 2-3 frequency")
lines(years, af_over_time(out_nmf)[, ppq], lwd = 2, col = "firebrick")
legend("topleft", legend = c("no non-malarial fevers", "with non-malarial fevers"),
       col = c("steelblue", "firebrick"), lwd = 2, bty = "n")

Whether this speeds resistance up or slows it down is not obvious in advance. Extra treatment selects for resistance, but it also removes infections and lengthens the population’s time under prophylaxis, which reduces transmission. That trade-off is one of the more interesting things the model can be used to examine.


Resistance beyond cure rates

Two further mechanisms change what resistance does, beyond the probability of being cured.

Slow parasite clearance. If treatment succeeds but the individual is carrying a strain resistant at any of the treating drug’s barcode_positions, they remain in the treated state for an extra dur_SPC days before moving to prophylaxis, and keep only the resistant strains. This represents delayed clearance, and gives resistant parasites a longer window in which to be transmitted. Note that this is driven by the drug’s own resistance positions, not by artemisinin_loci.

Gametocyte and oocyst effects. vector_adaptation_list_create() holds gametocyte_sterilisation_flag, gametocyte_sterilisation and oocyst_reduction_by_artemisinin, which modify how well a recently treated host infects mosquitoes. These are off by default. They are the natural place to represent a transmission blocking drug, and are discussed in detail in the adding a new drug vignette, which also notes a discrepancy between the intent and the implementation that you should be aware of before using them.


Where next